Novartis Says Knew About Zolgensma Data Problems Before U.S. Approval
New York: Drugmaker Novartis On Wednesday Acknowledged That There Were Discrepancies With Data It Had Submitted To Regulators For Approval Of Its More Than $2 Million Gene Therapy Zolgensma, But Delayed Notifying Authorities Until It Completed Its Internal Investigation.Novartis Faces Possible Civil Or Criminal Penalties From The U.S. Food And Drug
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!